We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on antiretroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.
References
[1]
World Health Organization (2015) Global Tuberculosis Report, 2014 (Drug-Resistant TB, Surveillance and Response) World Health Organization. Geneva, Switzerland. [WHO/ HTM/TB/2015.07].
[2]
Central Tuberculosis Division, Directorate General of Health Services (2012) Revised National Tuberculosis Control Programme, Guidelines on programmatic management of drug-resistant tuberculosis (PMDT) in India. Available at:
https://www.medbox.org/guidelines-on-programmatic-management-of-drug-resistant-tb-pmdt-in-india-1/preview
[3]
Macgregor A.E. and Somner, A.R. (1954) The Anti-Thyroid Action of Para-Aminosalicylic Acid. The Lancet, 264, 931-936. http://dx.doi.org/10.1016/S0140-6736(54)92552-0
[4]
Drucker, D., Eggo, M.C., Salit, I.E. and Burrow, G.N. (1984) Ethionamide-Induced Goitrous Hypothyroidism. Annals of Internal Medicine, 100, 837-839.
http://dx.doi.org/10.7326/0003-4819-100-6-837
[5]
Silva, G.A., Andrade, M.C., Suguide, A., et al. (2015) Association between Antiretrovirals and Thyroid Diseases: Across-Sectional Study. Archives of Endocrinology and Metabolism, 59, 116-122. http://dx.doi.org/10.1590/2359-3997000000023
[6]
Modongo, C. and Zetola, N.M. (2012) Prevalence of Hypothyroidism among MDR-TB Patients in Botswana. International Journal of Tuberculosis and Lung Diseases, 16, 1561-1562.
http://dx.doi.org/10.5588/ijtld.12.0403
[7]
Satti, H., Mafukidze, A., Jooste, P.L., et al. (2012) High Rate of Hypothyroidism among Patients Treated for MDR-TB in Lesotho. International Journal of Tuberculosis and Lung Diseases, 16, 468-472. http://dx.doi.org/10.5588/ijtld.11.0615
[8]
Andries, A., Isaakidis, P., Das, M., et al. (2013) High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai, India. PloS One, 10, e78313. http://dx.doi.org/10.1371/journal.pone.0078313
[9]
Garber, J.R., Cobin, R.H., Gharib, H., et al. (2012) Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22, 1200-1235.
http://dx.doi.org/10.1089/thy.2012.0205
[10]
Akshata, J.S., Swapna, R., Chakraboty, A. and Somashekar M. (2015) Hypothyroidism in MDR-TB Treatment—Rare Occurrence, but a Major Concern. Egyptian Journal of Chest Diseases and Tuberculosis, 64, 671-674. http://dx.doi.org/10.1016/j.ejcdt.2015.03.022
